This HTML5 document contains 73 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00894/identifier/national-drug-code-directory/
foafhttp://xmlns.com/foaf/0.1/
n22http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00894/identifier/chemspider/
n15http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB00894/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB00894/identifier/pharmgkb/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00894/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n21http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n19http://www.drugs.com/cdi/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00894/identifier/pubchem-compound/
n18http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00894/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00894/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00894/identifier/drugbank/

Statements

Subject Item
n2:DB00894
rdf:type
n3:Drug
n3:description
An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer. [PubChem]
n3:group
approved
n3:indication
For palliative treatment of advanced breast cancer in postmenopausal women.
n3:manufacturer
n16:271B599F-363D-11E5-9242-09173F13E4C5 n16:271B59A0-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00894 n20:DB00894
dcterms:title
Testolactone
adms:identifier
n6:13172 n7:DB00894 n8:PA164743056 n9:13769 n10:46508076 n11:0003-0690-50 n13:9460 n23:C02197 n24:D00153
n3:mechanismOfAction
Although the precise mechanism by which testolactone produces its clinical antineoplastic effects has not been established, its principal action is reported to be inhibition of steroid aromatase activity and consequent reduction in estrone synthesis from adrenal androstenedione, the major source of estrogen in postmenopausal women. Based on in vitro studies, the aromatase inhibition may be noncompetitive and irreversible. This phenomenon may account for the persistence of testolactone's effect on estrogen synthesis after drug withdrawal.
n3:packager
n16:271B599C-363D-11E5-9242-09173F13E4C5 n16:271B599D-363D-11E5-9242-09173F13E4C5 n16:271B599E-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
No clinical effects in humans of testolactone on adrenal function have been reported; however, one study noted an increase in urinary excretion of 17-ketosteroids in most of the patients treated with 150 mg/day orally. It is metabolized to several derivatives in the liver, all of which preserve the lactone D-ring. These metabolites, as well as some unmetabolized drug, are excreted in the urine.
n3:synonym
D-Homo-17a-oxaandrosta-1,4-diene-3,17-dione 1,2-Didehydrotestololactone Testolattone (4AS,4br,10ar,10bs,12as)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-F]chromene-2,8(4bh)-dione 1-Dehydrotestololactone Testolactone Testolactona Testolactonum delta(1)-Testololactone Teslac 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone
n3:toxicity
Oral LD<sub>50</sub>s in mouse and dog are 1630 mg/kg and 593-926 mg/kg, respectively.
n3:proteinBinding
~85%
n3:synthesisReference
Ivan Gilbert, Michael White, "Fermentation method for the preparation of testolactone by fusarium species." U.S. Patent US20060292666, issued December 28, 2006.
n21:hasConcept
n22:M0021194
foaf:page
n18:testolactone.htm n19:testolactone.html
n3:IUPAC-Name
n4:271B59A5-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B59AB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B59AA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B59A7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B59A8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B59A9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B59A3-363D-11E5-9242-09173F13E4C5 n4:271B59BB-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B59A4-363D-11E5-9242-09173F13E4C5 n4:271B59A1-363D-11E5-9242-09173F13E4C5 n4:271B59BD-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B59A2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B59B1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B59B2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B59AC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B59AD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B59AF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B59AE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B59B0-363D-11E5-9242-09173F13E4C5
n3:absorption
Testolactone is well absorbed from the gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
968-93-4
n3:category
n3:Bioavailability
n4:271B59B7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B59B9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B59BA-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B59BC-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B59B6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B59B5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B59B8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B59A6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B59B3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B59B4-363D-11E5-9242-09173F13E4C5